Loading
CTCF (Transcriptional repressor CTCF) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Breast cancer, Head and neck squamous cell carcinoma and 4 more.
Chromatin binding factor that binds to DNA sequence specific sites and regulates the 3D structure of chromatin. Binds together strands of DNA, thus forming chromatin loops, and anchors DNA to cellular structures, such as the nuclear lamina. Defines the boundaries between active and heterochromatic DNA via binding to chromatin insulators, thereby preventing interaction between promoter and nearby enhancers and silencers.
CIViC holds 3 clinical evidence items and 0 assertions across 3 variants. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.00, somatic mutation 0.91). IntOGen calls it a driver in 8 cohorts (0 activating, 8 loss-of-function), covering Acute Lymphoblastic Leukaemia, Invasive Breast Carcinoma, Head and Neck Squamous Cell Carcinoma, Endometrial Carcinoma.
In plain words · CTCF (Transcriptional repressor CTCF) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Breast cancer, Head and neck squamous cell carcinoma and 4 more.
CTCF (Transcriptional repressor CTCF) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Breast cancer, Head and neck squamous cell carcinoma and 4 more.
Chromatin binding factor that binds to DNA sequence specific sites and regulates the 3D structure of chromatin. Binds together strands of DNA, thus forming chromatin loops, and anchors DNA to cellular structures, such as the nuclear lamina.
No product in this corpus aims at CTCF yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CTCF: RNA low tissue specificity; high antibody staining in 36 normal tissues; highest cancer staining lymphoma (12 of 12 high). Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Endometrial cancer, Breast cancer (all types), Head and neck squamous cell carcinoma, Leukaemia, Lymphoma, Colorectal cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P49711; CIViC gene CTCF; IntOGen CTCF; Human Protein Atlas CTCF tissue; Open Targets ENSG00000102974 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Filippova G.N. et al, Mol. Cell. Biol, 1996, "An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes". Source.
Sources: HGNC HGNC:13723 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49711 (protein name, function text, keywords and locations (REST API)); CIViC gene CTCF (3 evidence items, 0 assertions, 3 variants; diseases: (GraphQL API, CC0)); Open Targets ENSG00000102974 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: colorectal cancer 0.52, endometrial cancer 0.59, acute lymphoblastic leukaemia 0.51, non-Hodgkin lymphoma 0.53, breast cancer 0.53, leukaemia 0.56 (GraphQL API, CC0)); IntOGen CTCF (driver in 8 cohorts (Act 0, LoF 8); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Chromatin binding factor that binds to DNA sequence specific sites and regulates the 3D structure of chromatin. Binds together strands of DNA, thus forming chromatin loops, and anchors DNA to cellular structures, such as the nuclear lamina. Defines the boundaries between active and heterochromatic DNA via binding to chromatin insulators, thereby preventing interaction between promoter and nearby enhancers and silencers. Participates in the allele-specific gene expression at the imprinted IGF2/H19 gene locus. On the maternal allele, binding within the H19 imprinting control region (ICR) mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to IGF2. Mediates interchromosomal association between IGF2/H19 and WSB1/NF1 and may direct distant DNA segments to a common transcription factory. Location: Nucleus, nucleoplasm; Chromosome; Chromosome, centromere (UniProt). Locus 16q22.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Caudate, Hippocampus, Oral mucosa, Prostate, Seminal vesicle, Soft tissue, Testis.
HPA CTCF tissue · HPA CTCF pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CTCF" OR ABSTRACT:"CTCF" OR TITLE:"CCCTC-binding factor" OR ABSTRACT:"CCCTC-binding factor" OR TITLE:"Transcriptional repressor CTCF" OR ABSTRACT:"Transcriptional repressor CTCF" OR TITLE:"FAP108" OR ABSTRACT:"FAP108" OR TITLE:"CFAP108" OR ABSTRACT:"CFAP108") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CTCF, not a curated reading list.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.
Shares Leukaemia (all types), CIViC, IntOGen, Head and neck squamous cell carcinoma.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, Breast cancer (all types).
Shares Leukaemia (all types), Endometrial cancer, CIViC, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Breast cancer (all types), Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Endometrial cancer, CIViC, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Breast cancer (all types).